Released Aug 10, 2023, after the close
10-Q filed Aug 10, 2023, 41 days after period end · 0000950170-23-041314
Q2 2023 · 10-Q
Revenue$269.00K$269.00K −70.0% vs Q2 2022+20.6% vs Q1 2023
Net Income-$11.90M-$11.90M N/M vs Q2 2022N/M vs Q1 2023
EPS Diluted-$0.23-$0.23 N/M vs Q2 2022N/M vs Q1 2023
Operating Income-$12,890,000N/M
Operating Cash Flowderived-$18,564,000N/M
Margins · derived
Operating margin-4791.8%−1881.1 pt vs Q2 2022
Net margin-4423.8%−1220.7 pt vs Q2 2022
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $269.00K | $896.00K | $2.11M | $51.00K |
| Net Income | -$11.90M | -$28.70M | -$18.60M | -$17.50M |
| EPS Diluted | -$0.23 | -$0.87 | -$0.63 | -$0.85 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR